Sodium Citrate
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Sodium Citrate: Papillary conjunctivitis
One-Sentence Summary
Sodium citrate is a buffering (antacid) agent, originally associated with acid-related upper gastrointestinal and upper respiratory conditions such as peptic ulcer disease, gastroesophageal reflux disease, dyspepsia and the common cold. The TxGNN model predicts it may be effective for papillary conjunctivitis, but there are no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sodium citrate is a buffering agent and antacid. Its use in acid-related gastrointestinal conditions is biologically consistent, and its listed upper respiratory indications may relate to the predicted indication through related tissue and disease categories.
The link to papillary conjunctivitis is speculative. One plausible but unsupported idea is a buffering or mild antiallergic effect on the ocular surface. The score of 0.9995 comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, such as other conjunctivitis and upper respiratory conditions, not biological evidence or demonstrated clinical benefit.
Other predictions for this drug show the same pattern. These include nasal cavity disease, acute laryngopharyngitis, stomach disease, postgastrectomy syndrome, gastroduodenitis, familial visceral myopathy, rosacea conjunctivitis and allergic urticaria. Only stomach disease and gastroduodenitis have any retrieved literature, and that literature is indirect. For example, the stomach disease results are mostly preclinical gastric cancer studies that combine sodium citrate with 3-bromopyruvate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 201195 | Serocit 46.7% Injection | Vial of 1 injection | Not stated |
| 36112 | Cool Syrup | Bottle of 200 ml syrup | Not stated |
Safety Considerations
- Drug Interactions: 114 interactions were identified in total. The main ones are:
- Major: Aluminum hydroxide.
- Moderate: Doxycycline, minocycline, tetracycline, levofloxacin, acetylsalicylic acid, iron, rosuvastatin, acalabrutinib, ephedrine and pseudoephedrine.
- Minor: Sulfonylureas (acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, tolbutamide), lactulose and misoprostol.
- Disease-level cautions from the knowledge graph (these are not label text): hypertension, pancreatitis, adrenal insufficiency (including Addison disease), benign prostatic hyperplasia, anuria, impaired renal function, rhabdomyolysis, hypercalcemia, nephrocalcinosis, coronary artery disease and myocardial infarction, metabolic acidosis, and angle-closure glaucoma or ocular hypertension.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. No trials or publications were found, and there is no mechanism of action data. Both marketed Indian products are for non-ocular use (an injection and an oral syrup), and the available route compatibility has not been assessed.
To proceed, the following is needed:
- Mechanism of action data for sodium citrate.
- Package insert warnings and contraindications for the two Indian products.
- A targeted literature search on citrate buffers or citrate-containing preparations in ocular surface disease and allergic conjunctivitis.
- An assessment of whether a suitable ophthalmic formulation and route exist.
- Preclinical or early clinical data showing a benefit in papillary conjunctivitis.
- A review of whether another predicted indication with indirect gastrointestinal support, such as gastroduodenitis, would be a better candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.